Bharat Biotech BBV 152 Covaxin

Markiert sind besonders wichtige Quellen.

• Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study

  thelancet.com, hinzugefügt am 24.06.2022

• Study shows booster dose of Covaxin has neutralising effect on Omicron, Delta variants: Bharat Biotech Read more at: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-says-covaxin-booster-shot-neutralises-omi

  economictimes.indiatimes.com, hinzugefügt am 13.01.2022

• SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India

  jamanetwork.com, hinzugefügt am 11.01.2022

• Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study

  thelancet.com, hinzugefügt am 25.11.2021

• COVID-19: Totimpfstoff aus Indien in Phase-3-Studie wirksam

  aerzteblatt.de, hinzugefügt am 19.11.2021

• Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

  thelancet.com, hinzugefügt am 15.11.2021

• Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19

  thelancet.com, hinzugefügt am 15.11.2021

• WHO lässt siebten Corona-Impfstoff zu

  t-online.de, hinzugefügt am 04.11.2021

• Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

  thelancet.com, hinzugefügt am 20.09.2021

• COVID-19 Vaccination: Delhi AIIMS likely to complete Covaxin trial on kids by next week

  english.jagran.com, hinzugefügt am 19.07.2021

• Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2

  medrxiv.org, hinzugefügt am 17.07.2021

• Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial

  medrxiv.org, hinzugefügt am 03.07.2021

• Covaxin Phase 3 Trial Analysis Conclude: Vaccine 77.8% Effective Against Covid, 65.2% Against Delta Variant

  india.com, hinzugefügt am 03.07.2021

• Brazil suspends Covaxin contract after ‘serious accusations’ of irregularities

  theguardian.com, hinzugefügt am 01.07.2021

• Covaxin Phase 3 data in: Efficacy 77.8% against symptomatic Covid

  indianexpress.com, hinzugefügt am 30.06.2021

• FDA rejects emergency use authorization for Bharat Biotech’s Covaxin jab

  livemint.com, hinzugefügt am 11.06.2021

• Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152

  biorxiv.org, hinzugefügt am 09.06.2021

• Covaxin effective against coronavirus strains found in India, UK

  hindustantimes.com, hinzugefügt am 17.05.2021

• COVAXIN® - India's First Indigenous COVID-19 Vaccine

  bharatbiotech.com, hinzugefügt am 15.05.2021

• Covaxin found to neutralise 617 var .. Read more at: http://timesofindia.indiatimes.com/articleshow/82284139.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

  timesofindia.indiatimes.com, hinzugefügt am 29.04.2021

• Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

  biorxiv.org, hinzugefügt am 25.04.2021

• Covaxin neutralises double mutant strain: ICMR

  cnbctv18.com, hinzugefügt am 21.04.2021

• Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease

  bharatbiotech.com, hinzugefügt am 21.04.2021

• EXCLUSIVE-Ocugen plans to sell 100 mln Indian vaccine doses in U.S. in 2021

  reuters.com, hinzugefügt am 26.03.2021

• COVID-19 vaccine: Mexico experts recommend approving Bharat Biotech's Covaxin

  newindianexpress.com, hinzugefügt am 07.03.2021

• Covaxin vs Covishield: Your full guide

  indiatoday.in, hinzugefügt am 07.03.2021

• Bharat Biotech’s Covaxin has around 81% efficacy: What does this mean for India?

  indianexpress.com, hinzugefügt am 04.03.2021

• Covaxin is effective against UK variant, shows study: what this means for India

  indianexpress.com, hinzugefügt am 29.01.2021

• Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

  biorxiv.org, hinzugefügt am 27.01.2021

• India begins COVID-19 vaccination amid trial allegations

  thelancet.com, hinzugefügt am 22.01.2021

• Covaxin jabs possibly part of Bharat Biotech's Phase 3 trial

  deccanchronicle.com, hinzugefügt am 17.01.2021

• Vaccine makers in Asia rush to test jabs against fast-spreading COVID variant

  nature.com, hinzugefügt am 13.01.2021

• Covaxin: Concern over 'rushed' approval for India Covid jab

  bbc.com, hinzugefügt am 05.01.2021

• Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine

  pib.gov.in, hinzugefügt am 03.01.2021

• India's coronavirus vaccine approved by drugs experts

  reuters.com, hinzugefügt am 03.01.2021

Keine Quelle enthält diesen Text.